# Pharvaris

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pharvaris

- Industry: Biotechnology
- Headquarters: Zug, Switzerland
- Website: www.pharvaris.com
- Total disclosed funding: $162M
- Latest round: Series C (Nov 18, 2020)
- Investors on record: 10

## About

Founded in 2015 and based in Zug, Switzerland, Pharvaris GmbH operates as a clinical-stage biotechnology company that develops therapeutic orally-taken drugs for HAE (hereditary angioedema). The company has raised a total of USD 162.3 million over three funding rounds of series A, B, and C in the years 2016, 2019, and 2020 respectively led by investors Foresite Capital, Bain Capital, venBio, Idinvest Partners, Life Sciences Partners, etc. In November 2020, Pharvaris GmbH filed for an IPO (Initial Public Offering) prospectus. Further in February 2021, Pharvaris raised USD 165.41 million in an IPO, selling 8.27 million shares at USD 20 per share on the NASDAQ. As of January 2024, has offices in Switzerland, The Netherlands, and in the US and is led by its Director and CEO, Berndt Modig.

The company's medical R&D team focuses on bringing orally bioavailable small-molecule bradykinin B2-receptor antagonists to the market and treat HAE patients and other B2 receptor-mediated indications. The product pipeline includes PHA121 solution, PHVS416 soft capsule, and PHVS719 tablet. Pharvaris GmbH also offers RAPIDe-1, a clinical research study to determine the effectiveness of three different doses of the study drug in relieving symptoms associated with HAE attacks.

## Funding rounds

- Series C, Nov 18, 2020, $80M — Bain Capital, General Atlantic, Venrock, Viking Global Investors, Foresite Capital, VenBio, Cormorant Asset Management
- Series B, Sep 10, 2019, $66M — Bain Capital, Idinvest Partners, EQT Life Sciences, Venrock, Kurma Partners, Foresite Capital, VenBio
- Series A, Jun 1, 2015, $16M — Idinvest Partners, EQT Life Sciences, Kurma Partners

## Investors

- Idinvest Partners (https://capitalatlas.ai/funds/idinvest-partners) — Series A, Series B
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series A, Series B
- Kurma Partners (https://capitalatlas.ai/funds/kurma-partners) — Series A, Series B
- Bain Capital (https://capitalatlas.ai/funds/bain-capital) — Series B, Series C
- Venrock (https://capitalatlas.ai/funds/venrock) — Series B, Series C
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series B, Series C
- VenBio (https://capitalatlas.ai/funds/venbio) — Series B, Series C
- General Atlantic (https://capitalatlas.ai/funds/general-atlantic) — Series C
- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series C
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series C